One-dose HPV vaccination could eliminate cervical cancer in Canada

Canadian vaccination programs could switch to a 1-dose gender-neutral human papillomavirus (HPV) vaccination approach and eliminate cervical cancer, suggests new modeling in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.240787.

Countries around the world are looking at whether to move from a 2-dose to 1-dose HPV vaccination approach after a 2022 recommendation by the World Health Organization Strategic Advisory Group of Experts on Immunization based on clinical trial evidence. Human papillomavirus can cause cervical cancer and other diseases.

Researchers in Ontario and Quebec modeled various scenarios based on 1- and 2-dose approaches to inform recommendations from the Canadian National Advisory Committee on Immunization and the Comité sur l'immunisation du Québec.

This approach is a more efficient use of vaccine doses and is projected to help eliminate cervical cancer in Canada.

Regular monitoring of 1-dose protection is advised to detect signs of waning protection.

Source:

Canadian Medical Association Journal

Journal reference: